Stem Cell Clinic

Celltex To Initiate New Clinical Program As It Responds To FDA Letter

By Stem Cell Doctors

HOUSTON, Oct. 1, 2012 /PRNewswire/ --Celltex Therapeutics Corp. announced today that it has received a letter, dated Sept. 24, 2012, from the U.S. Food and Drug Administration. The letter stated the agency's opinion that the process Celltex uses to multiply adult stem cells is subject to FDA regulation as biological drug manufacturing. The issue is a key one as stem cell therapy for patient care outside of an academic institution is a new frontier, yet there are a variety of technologies being used throughout the United States, often creating complex legal and regulatory questions.

David Eller, CEO and President of Celltex, stated:

Celltex makes identical copies of an individual's own stem cells and therefore should not be subject to FDA regulation as drugs. However, the FDA said our process causes the cells to be considered biological drugs and thus is subject to those regulations. We respectfully but firmly disagree with the FDA and intend to contest the agency's opinion within its administrative procedures. We are considering all options as we work with the agency toward a resolution.

FDA's letter also repeats its earlier observations from an April inspection of Celltex's laboratory. While Celltex provided detailed responses in April, May, June, July and August, now FDA tells us it needs more information. We will answer FDA's questions in whatever detail the agency requests."

We will meet FDA's requirements, no matter how high the hurdles may be, to ensure access to this technology. Celltex remains fully committed to advance the most promising new field in human health in decades regenerative medicine. We also remain committed to doing so safely, and we will continue to comply with federal and state agency requirements.

As we work with the FDA, Celltex will continue to make advances on the frontier of regenerative medicine, and we expect to have several significant announcements in the coming weeks on these matters:

"Celltex is committed to developing the promise of regenerative medicine into a reality for doctors and their patients," Mr. Eller said. "We sponsor clinical trials to better understand the therapeutic impact and monitor the safety of adult stem cell therapy, and we are confident that our research will help implement effective treatments for patients suffering from a variety of medical conditions."

For more information on Celltex Therapeutics Corporation and its staff please visit http://www.CelltexBank.com.

About Celltex

Celltex Therapeutics Corporation is a leader in providing services for the rapidly expanding field of regenerative medicine.Specifically, Celltex purifies, multiplies, and stores adult adipose-derived mesenchymal stem cells and rigorously follows the standards of good manufacturing practices for human cell laboratories. Celltex's laboratory currently holds more than fourteen patents protecting methodology and quality control. The Celltex process ensures extracted adult stem cells are separated, multiplied and stored without any genetic alteration or exposure to stimulants to alter the cells' natural multiplication ability. Celltex is currently researching new methods and technology for banking and stem cell treatment therapies to further the field of regenerative medicine and document the therapeutic impact of adult stem cell therapies on various medical conditions.

See the original post:
Celltex To Initiate New Clinical Program As It Responds To FDA Letter

Stem-cell advocacy ‘moved the needle’

By Stem Cell Medicine

A beautiful, fresh face, Sabrina Cohen can stun you with her charm.

But she is far more. This 24-year-old, who has spent 10 years in a wheelchair as a result of a car accident, is battling to raise money for research and therapies that may eventually reverse paralysis and treat central nervous system impairments.

A native of Miami Beach, she is one of five leaders being honored by the Palm Beach-based Genetic Policy Institute at its eighth annual World Stem Cell Summit Dec. 4 at the Palm Beach County Convention Center in West Palm Beach. She is receiving the Inspirational Award.

This award brings a lot of meaning to my life and the path I have chosen to follow, she says of her founding of the nonprofit Sabrina Cohen Foundation.

This provides a platform for my foundation to inspire others and to share my hope for (stem cell) regeneration.

Other honorees include CBS 60 Minutes for its hard-hitting programs on unproven stem cell treatments; Susan Solomon, CEO of the New York Stem Cell Foundation; Alliance for Regenerative Medicine; and the Nebraska Coalition for Lifesaving Cures.

We recognize the dedicated individuals and organizations that positively impact the cause of stem-cell advancement aimed at finding cures and alleviating human suffering, said Bernard Siegel, executive director of GPI.

Through their positive actions, our honorees have moved the regenerative medicine needle, bringing closer the day when patients will be safely treated through these innovative technologies.

Previous Stem Cell Action awardees have included Maryland Governor Martin OMalley, Research!America, Juvenile Diabetes Research Foundation, Michael J. Fox, Robert Klein, Sherry Lansing, Palm Beacher A. Alfred Taubman and the National Association of Biology Teachers.

This year, panels will address advancing treatments for specific diseases and conditions including cancer, diabetes, HIV/AIDS, cardiovascular disease, spinal cord injury, paralysis, multiple sclerosis, ALS, Parkinsons, eye diseases and others.

The rest is here:
Stem-cell advocacy ‘moved the needle’

Histogenics Honored as a 2012 “Fierce 15” Company by FierceMedicalDevices

By Uncategorized

WALTHAM, Mass.--(BUSINESS WIRE)--

Histogenics, a regenerative medicine company combining cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration, announced today that it has been named to the FierceMedicalDevices Fierce 15 list, designating it as one of the leading medical device and diagnostic companies of 2012. FierceMedicalDevicesEditors Mark Hollmer and Damian Garde, in conjunction with Editor-in-Chief John Carroll and Executive Editor Ryan McBride, chose this years winners based on their top management teams, notable financial backing, and promising technologies and market opportunities.

We have worked hard over the past year, securing $49 million in financing and adding key new staff, investors and board members, so that we are now in the position to focus our full attention on continued successful clinical and regulatory execution for NeoCart cartilage regeneration implant, which is currently enrolling patients into the Phase 3 IND clinical study, and the EU regulatory development of our VeriCart cartilage repair scaffold, said Patrick ODonnell, President and Chief Executive Officer of Histogenics. We believe our product candidates have the potential to transform the treatment of cartilage injury with the goal of returning some of the estimated 1.8 million patients each year in the U.S. and E.U. that undergo arthroscopy for knee cartilage defects to their pre-injury level of activity.

Nailing down $49 million in financing in July reinforces the notion that this regenerative medicine company stands out for doing things differently.One example how: The company is well underway enrolling patients in a Phase 3 trial for NeoCart, a cartilage implant that uses a patients own cells to build it before treating cartilage lesions in the knee, said Hollmer.

NeoCart is an autologous neocartilage tissue implant in an ongoing Phase 3 clinical program that utilizes the patients own cells to regenerate cartilage in patients suffering from cartilage lesions in the knee.VeriCart, is a single-step, cell-free collagen scaffold uniquely designed to be used in conjunction with the patients own stem cells to repair small cartilage defects frequently observed in meniscal and anterior cruciate ligament repair procedures. Histogenics is seeking regulatory clearance in the European Union for VeriCart.

An internationally recognized e-newsletter reaching more than 34,000 medical device and diagnostic industry professionals, FierceMedicalDevices provides subscribers with a quick authoritative briefing on the days top stories, with a special focus on clinical studies, FDA/EMEA regulations and post-marketing. Sign up is free at http://www.fiercemedicaldevices.com/signup.

About FierceMarkets

FierceMarkets, a wholly owned subsidiary of Questex Media Group, is a leader in B2B emedia, providing information and marketing services in the telecommunications, life sciences, healthcare, IT, energy, government and finance industries through its portfolio of email newsletters, websites, webinars and live events. Every business day, FierceMarkets wide array of publications reaches more than 1.3 million executives in more than 100 countries.

About Histogenics

Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company ProChon BioTech. Histogenics flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials in which the NeoCart autologous tissue implants effectiveness is compared to that of standard microfracture surgery. Based in Waltham, Massachusetts, the company is privately held. For more information, visitwww.histogenics.com.

See original here:
Histogenics Honored as a 2012 “Fierce 15” Company by FierceMedicalDevices

Nuvilex Subsidiary Austrianova Singapore to Participate in AusBiotech 2012

By Uncategorized

SILVER SPRING, Md. and SINGAPORE, Oct. 2, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology provider of cell and gene therapy solutions, announced today its wholly-owned subsidiary, Austrianova Singapore Pte Ltd (ASPL) will attend this year's AusBiotech event.

The annual AusBiotech event this year will be held from October 30 - November 2 at the Melbourne Convention and Exhibition Centre, Melbourne, Australia. It has earned a reputation as the industry's premier biotechnology conference for the Asia Pacific region and has successfully expanded its relevance to the Australian and International Biotechnology industries by attracting more than 1100 participants from over 20 countries.

Dr Brian Salmons, CEO of ASPL said, "AusBiotech has grown in stature over the past several years. In prior years, we entered agreements with companies and found it to be one of the most valuable events for networking with new contacts. We anticipate meeting with companies with proprietary therapeutic cells, such as stem cells, that can leverage their technology with our Cell-in-a-Box(R) delivery system. We believe the new contacts we make will expand our customer base and increase the use of cell and gene therapy for making therapeutic products and treating diseases. We will also be promoting our Bac-in-a-Box(R) technology for the first time at this meeting and anticipate generating interest around its potential."

The Chief Executive of Nuvilex, Dr. Robert Ryan, stated "Attendance at this important biotech event in Australia and within easy reach of Southeast Asia will enable us to have increased exposure for our Cell-in-a-Box(R) and Bac-in-a-Box(R) live cell encapsulation technology and to showcase its immense versatility, thus providing our companies greater visibility at a time that such capabilities are becoming more important in the marketplace. It is our goal to bring more projects to fruition from this meeting as more companies today are looking to bring cellular-based therapy and product creation from the drawing board to reality and into regular use."

About Nuvilex

Nuvilex, Inc. (NVLX) is an international biotechnology provider of live therapeutically valuable, encapsulated cells and services for research and medicine. A great deal of work is ongoing to move Nuvilex and its Austrianova Singapore subsidiary forward. This was clearly apparent during Dr. Ryan's trip to Singapore and the advent of new developments in the company as a whole. Our company's own offerings will include cancer, diabetes, other treatments and capabilities using the company's cell and gene therapy expertise and live-cell encapsulation technology.

The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494

Safe Harbor Statement

This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

Read the rest here:
Nuvilex Subsidiary Austrianova Singapore to Participate in AusBiotech 2012

NeoStem to Present at Multiple Conferences in October

By Uncategorized

NEW YORK, Oct. 2, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that Company management and management of its subsidiary, Progenitor Cell Therapy ("PCT"), have been invited to present at multiple conferences in October.

RetailInvestorConferences.com

The RedChip 15th Annual Fall Small-Cap Conference

Regenerative Medicine Foundation 2012 Conference

2012 Stem Cell Meeting on the Mesa, 2nd Annual Investor and Partnering Forum

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

See the article here:
NeoStem to Present at Multiple Conferences in October

Educational Programs Offered as Part of Cryo-Save´s Cord Blood Awareness Months

By Stem Cell Treatment

ZUTPHEN, the Netherlands, October 2, 2012 /PRNewswire/ --

Cryo-Save Group promotes the awareness of cord blood storage and stem cell therapies at several local educational events held throughout Europe.

Cryo-Save continues its Cord Blood Awareness Months celebration by sponsoring educational events in the Netherlands, Italy and Spain during the months of October and November. It is events like these that Cryo-Save hopes to bring awareness of and research advancements for the stem cell industry.

Stem cells are becoming ever more important in the medical field as a way to treat a broad variety of malignant and non-malignant diseases. The U.S. National Marrow Donor Program sites cord blood as treatment for multiple myeloma, severe aplastic anaemia, beta thalassemia major, SCID and other inherited immune system disorders, and leukaemias and lymphomas. Patients suffering from sickle cell anaemia have been considered cured after being treated with stem cells.[1] Over 4,000 clinical trials using cord blood stem cells are taking place to treat diseases such as cerebral palsy, diabetes and autism with many more potential clinical trials continuing to develop.

"Cryo-Saves efforts to inform the medical professionals and community members about advances in regenerative medicine means that patients suffering from diseases treatable with stem cells can also become better informed, " says Dr. Cherie Daly, Medical Affairs Manager Cryo-Save. "Having a series of events and programs as part of Cord Blood Awareness Months makes an even stronger impact on the meaningfulness of this research and its application." Cryo-Save Group will continue its commitment to promoting the storage of cord blood and stem cells even after Cord Blood Awareness Months by offering several customer related promotions.

Cryo-Save Italy will hold a special meeting for midwives about stem cells, applications and Cryo-Saves storage services on October 2. Dr. Stefano Grossi, Cryo-Save Italy Scientific Director, will be there to present on stem cell applications. During the month of October Cryo-Save Italy will also offer several parent-to-be courses on similar topics in places all around Italy: Brescia, Venice, Bologna, Milan and others.

Midwives in the Netherlands are invited on October 4 to visit the Cryo-Save Laboratory in Niel, Belgium for a unique behind the scenes tour of the ultra-modern facility - an opportunity not available at most other cord blood banks. Attendees will have a chance to be given an update from Dr. Sally Sennitt, Cryo-Save Lab Director about the current applications of stem cells, treatable diseases and new clinical trials. Staff from Cryo-Save, the Netherlands will also report on the position and procedure of stem cell storage in the Netherlands and have a group discussion on the topic. "This event is our chance to give midwives information on the importance of stem cell storage and give them tools for helping parents become better informed of this option, " says Erica Dikkeboom, Cryo-Save Nederland.

--------------------------------------------------

1. University of Illinois at Chicago (2012, June 18). Chicago woman cured of sickle cell disease. ScienceDaily. Retrieved September 12, 2012, from http://www.sciencedaily.com/releases/2012/06/120618194714.htm

Crio-Cord, Cryo-Saves subsidiary in Spain, will hold a stem cell therapy symposium in Madrid on October 16 focusing on cutting edge therapies using umbilical cord stem cells and will also include current investigations using stem cells that are taking place in Madrid. The symposium will be attended by national and international speakers and is the first of its kind to take place in Madrid.

Follow this link:
Educational Programs Offered as Part of Cryo-Save´s Cord Blood Awareness Months

FDA Approves Stemedica Phase II Clinical Trial for Acute Myocardial Infarction With Ischemia Tolerant Mesenchymal Stem …

By Stem Cell Treatment

SAN DIEGO, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- via PRWEB - Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that the U.S. Food and Drug Administration (FDA) approved its application for an Investigational New Drug (IND) to assess the clinical effects of Stemedyne-MSC (Stemedica's human bone marrow-derived ischemia tolerant mesenchymal cells) in subjects with a myocardial infarct. The Phase IIa double-blinded randomized clinical trial will study approximately forty (40) patients. All patients will initially receive standard care including percutaneous transluminal coronary angioplasty (PTCA) and stenting and, upon completion, will be randomized to receive Stemedyne-MSC intravenously or placebo.

The clinical trial will address the prevalence of cardiovascular disease estimated to carry a global disease burden in excess of $400 billion each year. More than one million patients undergo PTCA and stenting in the Untied States annually; another 800,000 have the procedures each year in Europe.

Nabil Dib, M.D., MSc., F.A.C.C., Director of Cardiovascular Research at Mercy Gilbert and Chandler Regional Medical Centers, and an Associate Professor of Medicine and Director of Clinical Cardiovascular Cell Therapy at the University of California, San Diego, will serve as the principal investigator of the FDA-approved study. Dr. Nib commented, "We've learned from bench top research that not all stem cells are created equally. We believe that the ischemic tolerance of Stemedica's MSCs and the robustness of their protein array will translate into significant patient benefits post myocardial infarction."

Stemedica's interest in this indication was triggered by a successful randomized study in acute myocardial infarction conducted by the National Scientific Medical Center (NSMC) in Astana, Kazakhstan using Stemedyne-MSCs. The study was conducted under clinical protocol and in compliance with the ICH-E6 (Good Clinical Practice) guidelines and local laws. All patients signed an informed consent. Nineteen (19) patients in this study received Stemedyne-MSCs after PTCA and stenting. Administration of Stemedyne-MSC resulted in a statistically-significant decrease in inflammation as judged by the level of C-reactive protein, significant decrease in end-systolic and end-diastolic volume of left ventricle, as well as significant increase in the left ventricular ejection fraction (LVEF) from 38.4% to 54.7% at 6 months post administration, bringing this parameter to a normal range for healthy individuals (50-65%).

Professor Daniyar Jumaniyazov, M.D. Ph.D., principal investigator of the NSMC study commented, "The stem cell transplantation was safe and the procedure was well tolerated. No product-related adverse events were reported. Treatment of patients in this study resulted in improvement of overall and local contractive myocardium functions and also normalization of systolic and diastolic filling of the left ventricle as compared to the control group. Based upon the safety and efficacy results, we will soon conduct a Phase III myocardial infarct clinical trial at the NSMC with Stemedica's ischemia tolerant mesenchymal stem cells."

Lev Verkh, Ph.D., Stemedica Chief Regulatory and Clinical Development Officer commented, "Stemedica's FDA submission included data from the NSMC clinical trial, the results of which were also reported at the annual American College of Cardiology meeting in April, 2012. These results contrasted with reports, at the same conference, of minimal improvement in studies with autologous stem cells. In addition to the United States sites, the study will be duplicated at leading hospitals in Europe, Asia and the Middle East." With regard to the spectrum of stem cell treatment for cardiovascular disease, Dr. Verkh noted that, "Stemedyne-MSC has been approved for the treatment of chronic heart failure at Hospital Angeles, Tijuana, Mexico by COFEPRIS (the Mexican equivalent of the FDA)."

Jackie See, M.D., F.A.C.C., founder of interventional cardiology at the University of California, Irvine, noted, "In the days and weeks following a myocardial infarction we may have the ability to intervene with stem cells to minimize scarring, enhance the amount of functional heart tissue, and restore the microcirculation. Stemedica's ischemia tolerant mesenchymal stem cells are ideal for this purpose. I can foresee the day when all coronary stenting is accompanied by stem cell injection. It is not unreasonable to postulate that the anti-inflammatory and anti-fibrotic effects of the mesenchymal stem cells may have an impact on the incidence of restenosis, a common condition caused by blockage of the stents."

The Stemedyne-MSC product is uniquely manufactured to contain increased amounts of the important growth factors that combat ischemic damage. According to Nikolai Tankovich, M.D., Ph.D., President and Chief Medical Officer of Stemedica, "Our ischemia tolerant MSCs secrete increased amounts of vascular endothelial growth factor (VEGF), which is necessary for new blood vessel development and stromal cell-derived factor (SDF), which is responsible for rescuing dying cells. Stemedyne-MSCs also demonstrate significantly higher migratory abilities. As a company we are unique in our unparalleled scalability, with our master bank at two passages and the cells that go into patients having only been expanded four times. We have the ability to treat more than 500,000 patients with cells created from a single organ donation."

Stemedyne-MSC is one of the three adult allogeneic stem cell products developed by the Company. Other products include Stemedyne-NSC neural human stem cells and Stemedyne-RPE, retinal progenitor epithelial cells available in early 2013. All Stemedica products are unique in their ability to tolerate ischemic conditions.

About Stemedica Cell Technologies, Inc. http://www.stemedica.com

View post:
FDA Approves Stemedica Phase II Clinical Trial for Acute Myocardial Infarction With Ischemia Tolerant Mesenchymal Stem ...

Coffee sale raises $30,000 for Spokane woman’s stem cell transplant

By Stem Cell Doctors

by KREM.com

KREM.com

Posted on October 1, 2012 at 11:43 AM

Updated today at 1:53 PM

Spokane -- A local woman fighting for her life will receive more than $30,000 in community donations thanks to a fundraiser held over the weekend by Dutch Bros. Spokane.

The coffee company offered drinks for $2 Saturday, and owners donated $1 of each sale to Davis for a potentially life-saving stem cell transplant.

The 24-year-old suffers from CREST syndrome, an acronym for five diseases that have a long list rehabilitating symptoms. Cat has tried many things to cure the disease, but nothing has worked. Doctors say she has months to live, and she needs a stem cell treatment as soon as possible. If her organs harden too much, she will no longer be a candidate for the treatment.

San Francisco Giants pitcher Jeremy Affeldt, who hails from Spokane, pledged to match funds raised by Saturdays fundraiser.

The Cure for Cat Foundation hopes to raise $125,000 for the stem cell treatment.

Here is the original post:
Coffee sale raises $30,000 for Spokane woman’s stem cell transplant

Whitehead Members to Help Establish International Stem Cell Research Center

By Stem Cell Medical Center

Newswise CAMBRIDGE, Mass. (October 1, 2012) Three Members of the Whitehead Institute faculty are poised to play significant roles in the establishment of a new stem cell research center based at Skolkovo Institute of Science and Technology (Skolkovo Tech) in suburban Moscow.

Whitehead Founding Member Rudolf Jaenisch, and Members Richard Young and Peter Reddien, will contribute their research, educational, and entrepreneurial expertise to the Skolkovo Center for Stem Cell Research (SCSCR). The center is among the first of three core research facilities to be created at Skolkovo Tech, a private graduate research university in Skolkovo, Russia, established in 2011 in collaboration with Massachusetts Institute of Technology.

Skolkovo Techs research centersknown as Centers for Research, Education, and Innovation (CREIs) are intended to advance scientific understanding in a particular field, develop cutting-edge technologies for potential commercialization, attract world-class scientists to Skolkovo, and train the next generations of promising students. CREIs are international partnerships consisting of researchers from at least three universities or research institutes: Skolkovo Tech, a Russian university or institute, and a non-Russian university. As part of SCSCR, the Whitehead scientists will join a team under the direction of Peter Lansdorp, Director of the European Research Institute for the Biology of Aging at University of Groningen Medical Center UMCG in the Netherlands.

This is a very promising experiment, Lansdorp says. By stimulating international collaboration, it is certain to advance stem cell science while at the same time helping Russian studentstrained by leading stem cell scientists from Whitehead Institute and the Netherlandsto become productive scientists in Moscow."

Within SCSCR, Lansdorp, Jaenisch, Young, Reddien and others will tackle some of the most fundamental challenges to the development of stem-cell-based therapeutics, including optimizing methods for cellular reprogramming, pluripotent stem cell differentiation, and the identification of gene networks involved in stem cell regulation and regeneration.

Although funding details for the stem cell center are not yet final, Skolkovo officials say that a typical CREI receives about $10 million worth of funding, depending on the scope of each research program.

Skolkovos research centers are unique in their synergy between scientific knowledge and practical application, which originates through various institutes working together in a new way, says Skolkovo Tech President Edward Crawley. Russian researchers gain access to cutting edge technologies and the opportunity to integrate into the world's scientific community, our international partners will benefit from the academic knowledge and new ideas produced within Russian institutes, and Skolkovo Tech will attract the world's best scientists to create its educational and research programs.

Written by Matt Fearer

Go here to read the rest:
Whitehead Members to Help Establish International Stem Cell Research Center

Health Link Medical Center Introduces the Regenexx™ Orthopedic Stem Cell Treatments to the San Francisco Area

By Stem Cell Clinic

OCEANSIDE, Calif., Oct. 1, 2012 /PRNewswire/ --Health Link Medical Center, a national leader in regenerative interventional orthopedics and advanced biological cell therapies, today announced the planned opening of their new location in Mill Valley, California in October 2012. Health Link Medical Center's Oceanside, California clinic is currently California's only provider of Regenexx orthopedic platelet and autologous stem cell procedures.

Regenexx Procedures offer non-surgical treatment options for common joint injuries and degenerative conditions, such as osteoarthritis. The procedures utilize a patient's own stem cells to help heal damaged tissues, tendons, ligaments, bone, or cartilage. Regenexx patients experience less downtime and avoid the lengthy and painful rehabilitation periods that follow surgery.

"We're excited for the opportunity to bring Regenexx Procedures to the San Francisco area," said Dr. Norman Deitch, CEO of Health Link Medical Center. "Patients regularly travel across the country for the opportunity to receive these leading non-surgical treatments. This expansion makes them conveniently accessible to the millions of individuals in northern California."

The Mill Valley Center will include a biological cell laboratory, capable of the advanced laboratory processing of platelets and stem cells required for the same-day procedures. Paul Handleman, D.O., has joined Health Link with an extensive interventional orthopedic background and has been in practice in Marin County, California for more than 15 years. Dr. Handleman has undergone advanced training at the Regenexx / Centeno-Schultz home clinic in Broomfield, Colorado.

Regenexx Procedures are currently performed at Health Link's Oceanside, CA. location. The Mill Valley Center opening is slated for October 2012 and Health Link is already scheduling patients for the new location. For more information, visit http://www.healthlinkcenter.com or call 800-281-3757.

About Health Link Medical Center

Based in Oceanside, California, Health Link Medical Center is a leader in regenerative interventional orthopedics and advanced biological cell therapies. Health Link is California's first provider of Regenexx Stem Cell and Blood Platelet Procedures. Learn more at http://www.healthlinkcenter.com.

About Regenexx and the Regenexx Physician Network

Regenexx Procedures offer non-surgical treatments for joint injuries and degenerative conditions. For more information on Regenexx Procedures and the Regenexx Physician Network, visit: http://www.regenexx.com

Contact:

See the rest here:
Health Link Medical Center Introduces the Regenexx™ Orthopedic Stem Cell Treatments to the San Francisco Area

→←